BMC Cancer最新文献

{"title":"Barriers and facilitators to anal cancer screening among men who have sex with men: a systematic review with narrative synthesis.","authors":"IatTou Sam, Wen Dang, NgaTeng Iu, ZiYue Luo, Yu-Tao Xiang, Robert David Smith","doi":"10.1186/s12885-025-13980-w","DOIUrl":"10.1186/s12885-025-13980-w","url":null,"abstract":"<p><strong>Background: </strong>Increasing trends of anal cancer among men who have sex with men (MSM) highlight the importance of anal cancer screening. However, the screening rate of anal cancer among MSM remains relatively low. This systematic review aims to identify and critically evaluate studies examining barriers and facilitators influencing MSM's participation in anal cancer screening.</p><p><strong>Methods: </strong>Systematic searches were performed in five databases (Web of Science, Medline, Embase, PsycINFO, and CINAHL). Evidence from qualitative, quantitative, and mixed methods studies was extracted and synthesized. Mixed Methods Appraisal Tool (MMAT) was used for quality assessment. Two researchers underwent selection and appraisal independently. PROSPERO registration number: CRD42024601449.</p><p><strong>Results: </strong>305 studies were identified with a total of 32 studies included, including 11 qualitative studies, 18 quantitative studies, and 3 mixed methods studies. The barriers and facilitators to anal cancer screening were categorized into four domains: individual factors, healthcare system factors, healthcare provider factors, and screen-related factors. Among the four domains, the most frequently reported barriers and facilitators to anal cancer screening were individual factors. A lack of knowledge about the risks of HPV, anal cancer, and anal screening (n = 16) was the most significant barrier. In contrast, a greater perceived understanding of anal cancer and screening (n = 6) was identified as the primary facilitator.</p><p><strong>Conclusions: </strong>This systematic review provided a comprehensive assessment of barriers and facilitators to anal cancer screening among MSM, highlighting the need for targeted comprehensive intervention programs to enhance acceptance of screening. Implementing effective strategies to address potential barriers and promote facilitators across all domains of public health could significantly increase screening uptake.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"586"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963451/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smoking is a significant contributor to intraoperative blood loss in metastatic spinal tumor surgery: a propensity score analysis.","authors":"Xuedong Shi, Yunpeng Cui, Bailin Wang, Yuanxing Pan, Bing Wang, Yong Qin, Mingxing Lei","doi":"10.1186/s12885-024-13321-3","DOIUrl":"10.1186/s12885-024-13321-3","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Metastatic spinal tumors pose a significant challenge regarding intraoperative blood loss. Identifying risk factors for intraoperative blood loss is crucial for appropriate surgical planning and early intervention. However, current studies have not comprehensively evaluated risk factors for predicting intraoperative blood loss. This study aims to determine whether smoking significantly contributes to intraoperative blood loss among metastatic spinal tumors and to investigate other potential risk factors.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study analyzed 252 patients with metastatic spinal disease who underwent posterior decompressive surgery, and the primary outcome measured was intraoperative blood loss, with massive intraoperative blood loss defined as exceeding 2500 mL. Propensity score matching analysis was employed to analyze the influence of smoking on intraoperative blood loss. In addition, subgroup analysis was performed based on smoking status before and after propensity score analysis. Multivariate analysis was used to analyze the relationship between smoking and intraoperative blood loss. To assess the predictive value of smoking status for intraoperative massive blood loss, we conducted an analysis using the Area Under the Receiver Operating Characteristic Curve (AUROC), and the corresponding Area Under the Curve (AUC) values were subsequently calculated.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Before conducting the propensity score analysis, the study found that smoking patients had a significantly higher volume of intraoperative blood loss (1938.30 mL vs. 1722.32 mL, P = 0.014) and a greater incidence of massive intraoperative blood loss (36.4% vs. 20.1%, P = 0.008) compared to non-smokers. After adjusting for propensity scores, the results showed that smokers still had a higher volume of intraoperative blood loss (1938.30 mL vs. 1703.41 mL, P = 0.019) and a higher proportion of massive intraoperative blood loss (39.7% vs. 14.9%, P = 0.002) than non-smokers. Multiple linear regression analysis confirmed that smoking status was significantly associated with intraoperative blood loss before (Estimate = 1.410, P = 0.001) and after (Estimate = 1.443, P = 0.010) propensity score matching analysis. Additionally, the logistic regression demonstrated that smokers were 2.268 times (95% CI: 1.272-4.044) more likely to experience intraoperative massive blood loss compared to nonsmokers before propensity score analysis (P = 0.005). After propensity score analysis, the fold increase in risk further rose to 3.764 (95% CI: 1.643-8.621), indicating an even stronger association between smoking and intraoperative blood loss (P = 0.002). Furthermore, the AUC value increased from 0.596 (95% CI: 0.527-0.666) for smoking status before propensity score matching analysis to 0.660 (95% CI: 0.567-0.753) after propensity score matching analysis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Smoking is a significant risk factor for increased in","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"594"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143762448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: SIRT7 affects the proliferation and apoptosis of papillary thyroid cancer cells by desuccinylation of LATS1.","authors":"Qinghua Li, Gang Pu","doi":"10.1186/s12885-025-13977-5","DOIUrl":"10.1186/s12885-025-13977-5","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"578"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959771/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vagal nerve activity and cancer prognosis: a systematic review and meta-analysis.","authors":"Wen-Bo Huang, Heng-Zhou Lai, Jing Long, Qiong Ma, Xi Fu, Feng-Ming You, Chong Xiao","doi":"10.1186/s12885-025-13956-w","DOIUrl":"10.1186/s12885-025-13956-w","url":null,"abstract":"<p><strong>Background: </strong>The prognostic significance of vagal nerve (VN) activity, as measured by heart rate variability (HRV) in cancer patients remains a subject of debate. The aim of this meta-analysis was to evaluate the association between various HRV parameters and cancer prognosis.</p><p><strong>Methods: </strong>We conducted an extensive search of the PubMed, Embase, Cochrane, and Web of Science databases and compared the overall survival (OS) of cancer patients with high and low HRV. The data type was unadjusted hazard ratio (HR). Random or fixed-effects models were used to calculate the pooled HR along with the 95% Confidence Interval (CI). We used funnel plot analysis to evaluate potential publication bias.</p><p><strong>Results: </strong>A total of 11 cohort studies were included with 2539 participants. The methodological quality of the included studies is generally high. Compared with low standard deviation of normal-to-normal intervals (SDNN) group, higher SDNN was a protective factor for OS in patients with cancer (I² = 66%, HR = 0.59, 95% CI: 0.46-0.75, P < 0.0001). Compared with low root mean square of successive differences (RMSSD) group. The prognostic value of RMSSD did not reach statistical significance (I² = 0%, HR = 0.85, 95% CI: 0.70-1.03, P = 0.11). Among the frequency domain indicators, higher high-frequency power HRV (HF-HRV) and low-frequency power HRV (LF-HRV) were associated with significantly longer overall survival compared to the low HF-HRV and LF-HRV groups (I² = 6%, HR = 0.59, 95% CI: 0.43-0.80, P = 0.006 and I² = 74%, HR = 0.45, 95% CI: 0.22-0.93, P = 0.03). In the nonlinear indicators, higher maximal diagonal line length (Lmax), mean diagonal line length (Lmean), percent of recurrence (REC), and determinism (DET) were associated with poorer tumor OS. The funnel plot shows that there is no publication bias in the study.</p><p><strong>Conclusions: </strong>The findings of this study demonstrate that HRV parameters, particularly SDNN, HF-HRV, and nonlinear indices, exhibit predictive value for prognosis in cancer. Furthermore, it can be inferred that elevated VN activity may predict prolonged survival outcomes. However, these findings should be interpreted with caution due to the heterogeneity observed across included studies. Future research should prioritize prospective studies with standardized measurement protocols to validate these associations.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"579"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960028/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor immune microenvironment in adenoid cystic carcinoma of the lacrimal gland: relationship with histopathology and prognosis.","authors":"Yi Zhang, Zhipeng Guo, Jie Sun, Yingwen Bi, Rongrong Cai, Rui Zhang, Hui Ren, Jiang Qian, Fengxi Meng","doi":"10.1186/s12885-025-13438-z","DOIUrl":"10.1186/s12885-025-13438-z","url":null,"abstract":"<p><strong>Purpose: </strong>To quantitatively investigate the pathological subtypes of lacrimal gland adenoid cystic carcinoma (LGACCs), the tumor immune microenvironment in each pathological subtype, and the relation to survival.</p><p><strong>Methods: </strong>In this retrospective study, the tumor subtype was determined by H&E staining. Multiplex immunochemistry was performed to define specific immune cells. The tumor immune microenvironment (TIME) was sketched by sequential image scanning and reconstructed by a cytometry platform.</p><p><strong>Results: </strong>Eighteen patients with adequate paraffin blocks diagnosed with LGACC from 2012 to 2021 were included in this study. Thirteen patients out of the eighteen patients (72.2%)showed a mixture of different pathological subtypes. Each pathological subtype took different percentages on different tumors. The cribriform was the most common subtype, taking an overall percentage of 39%. The rest of the pathological subtypes were tubular (19%), basaloid (17%), cribriform and tubular mixture (C + T) 14%. The sclerosing and comedocarcinomic subtypes were the least seen in LGACC, taking a percentage of 11% altogether. Patients with cribriform dominant component had better overall survival than the non-cribriform dominant patients. Patients with basaloid dominant component had worse clinical outcomes than the non-basaloid dominant ones. The TIME showed high immunogenicity in the tumor margin but declined in the tumor areas. Pathological subtypes rather than individual differences determined the TIME phenotype. The cribriform subtype possessed more immune cell infiltration than other pathological subtypes.</p><p><strong>Conclusions: </strong>LGACC is composed of multiple pathological subtypes. Each pathological subtype takes different percentages on different tumors, which is related to the prognosis. TIME pattern in LGACC varies among different pathological subtypes, which could indicate novel strategies in immunotherapy.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"581"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analytical validation of the Percepta Nasal Swab classifier; an RNA next-generation sequencing assay for the assessment of lung cancer risk in pulmonary nodules.","authors":"Shuyang Wu, Ruochen Jiang, Grazyna Fedorowicz, Mei Wong, Janna S Chamberlin, Lori Lofaro, P Sean Walsh, Giulia C Kennedy, Yangyang Hao, Jing Huang, Bill Bulman","doi":"10.1186/s12885-025-13683-2","DOIUrl":"10.1186/s12885-025-13683-2","url":null,"abstract":"<p><strong>Background: </strong>A novel molecular diagnostic test, Percepta Nasal Swab (PNS), was developed as a noninvasive lung cancer biomarker to aid in risk assessment for indeterminate pulmonary nodules in individuals who smoke or have previously smoked. Prior research has shown that exposure of the airway epithelium to cigarette smoke results in epithelial gene expression alterations throughout the respiratory tree that reflect the risk of lung cancer in a pulmonary nodule. The PNS classifier leverages this concept using whole transcriptome sequencing (RNASeq) of cells collected from the nasal epithelium and provides \"high\", \"intermediate\" and \"low risk\" classification calls to help guide clinical management decisions. The clinical validity of the PNS test was established on an independent validation set and demonstrated favorable sensitivity and specificity. This study aims to evaluate the analytical validity of the PNS test performance in our CLIA (Clinical Laboratory Improvement Amendments) laboratory.</p><p><strong>Methods: </strong>The reproducibility between RNASeq runs within a laboratory and the accuracy between laboratories were estimated and compared against the performance-based acceptance criterion. The impacts from varying RNA input amount, genomic DNA and blood RNA interference were evaluated to demonstrate the analytical sensitivity and specificity of the PNS test results to known conditions that may occur in routine laboratory processing.</p><p><strong>Results: </strong>Based on modeling the impact on clinical sensitivity/specificity, PNS test classifier scores can allow up to 0.776 score units of added noise/variability before any performance metrics drop below the pre-specified requirements. This allowable variability is six-fold higher than the observed variability estimated between runs and between laboratories under routine testing conditions, which are each less than 2% of the 98th percentile score range. In addition, PNS test results are shown to be robust against RNA input variation from 50 ng to 15 ng, up to 30% of genomic DNA by nucleic mass interference, and up to 14% of blood RNA interference.</p><p><strong>Conclusions: </strong>This study provided sufficient evidence for the accuracy, reproducibility, sensitivity, and specificity of the PNS molecular test and supported its utilization in clinical testing.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"577"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological characteristics and the relationship of PD-L1 status, tumor mutation burden, and microsatellite instability in patients with esophageal carcinoma.","authors":"Suyao Li, Yongling Yu, Yirong Xu, Yue Zhou, Junxing Huang, Jinghao Jia","doi":"10.1186/s12885-025-13938-y","DOIUrl":"10.1186/s12885-025-13938-y","url":null,"abstract":"<p><strong>Background: </strong>Despite significant advancements in the field of immunotherapy for esophageal cancer in recent years, only a minority of patients respond to these treatments, and effective predictive biomarkers remain elusive. Biomarkers such as programmed cell death 1 ligand 1 (PD-L1), tumor mutational burden (TMB), and microsatellite instability (MSI) are pivotal in guiding immune checkpoint inhibitor therapies. This study aimed to explore the correlation between the three biomarkers in patients with esophageal carcinoma.</p><p><strong>Methods: </strong>We collected one hundred esophageal squamous cell carcinoma (ESCC) tumor samples from patients who have been undergoing radical resection of esophageal carcinoma. Each tissue sample was divided into two parts for next-generation sequencing (NGS) and immunohistochemical staining. Mutations were identified using the NGS database, and TMB was calculated. Multiplex PCR targeting five loci (NR21, NR24, NR27, BAT25, and BAT26) was used to evaluate MSI. PD-L1 expression was determined through immunohistochemical analysis.</p><p><strong>Results: </strong>Among the 100 ESCC patients, 54% (54/100) exhibited positive PD-L1 expression, 57% (57/100) demonstrated high TMB (TMB-H), and only 1% (1/100) had high MSI (MSI-H). Within the subset of TMB-H cases, 32 showed positive PD-L1 expression, with a single case displaying high expression of all three biomarkers, and 21 cases displaying low expression of all three biomarkers. There was no statistical association between PD-L1 expression levels and TMB. Further analysis showed a significant correlation between TNM staging and PD-L1 expression levels in ESCC tissues, with higher positive rates of PD-L1 expression observed in advanced stages. Similarly, a significant relationship was observed between TMB and lymph node metastasis.</p><p><strong>Conclusions: </strong>Based on our preliminary results, TMB and PD-L1 can serve as potential early screening clinical biomarkers and molecular targets for immune treatment in ESCC. However, there is no apparent statistical association between TMB and PD-L1 expression levels. Furthermore, PD-L1 and TMB may independently influence the efficacy of immunotherapy, highlighting the inadequacy of single-marker detection in effectively predicting treatment outcomes.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"576"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11956183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a m6A- and ferroptosis-related LncRNA signature for forecasting prognosis and treatment response in cervical cancer.","authors":"Kaiting Wen, Lili Wang, Huancheng Su, Lijun Yu, Sanyuan Zhang, Meiyan Wei, Yaling Wang, Le Zhao, Yan Guo","doi":"10.1186/s12885-025-13974-8","DOIUrl":"10.1186/s12885-025-13974-8","url":null,"abstract":"<p><strong>Background: </strong>N6-methyladenosine (m6A) and ferroptosis are involved in the development and prognosis of various cancers via long noncoding RNAs (lncRNAs). This study aimed to investigate the cervical cancer subtypes based on m6A-and ferroptosis-related lncRNAs (mfrlncRNAs) and to construct a mfrlncRNA signature to predict cervical cancer prognosis and treatment response.</p><p><strong>Methods: </strong>mfrlncRNA-related cervical cancer subtypes were identified based on public datasets, and their differences in terms of prognosis, immune cell infiltration, and biological mechanisms were compared. Moreover, prognosis-related mfrlncRNAs were identified to construct a prognostic signature. A nomogram was constructed based on the independent prognostic factors. Immune characteristics, immunotherapy response predictions, and drug sensitivity analyses were performed for both risk groups. Furthermore, quantitative PCR was performed to validate the differential expression of the signature mfrlncRNAs in clinical samples.</p><p><strong>Results: </strong>In total, 549 differentially expressed mfrlncRNAs were identified between cervical cancer and normal samples. Two mfrlncRNA-related cervical cancer subtypes that exhibited distinct prognoses, immune characteristics, and biological mechanisms were identified. A prognostic signature was developed using six prognostic mfrlncRNAs: AC016065.1, AC096992.2, AC119427.1, AC133644.1, AL121944.1, and FOXD1_AS1. This prognostic signature exhibited high performance in predicting the prognosis of cervical cancer. Moreover, RiskScore and stage were identified as independent prognostic factors, and a nomogram was constructed to accurately forecast overall survival. Furthermore, patients in the low-risk group had a more active immunotherapy response and were more sensitive to chemotherapeutic drugs such as imatinib. Upregulated expression of AC119427.1, AC133644.1, AL121944.1, and FOXD1_AS1 was observed in the tumor samples.</p><p><strong>Conclusions: </strong>The six-mfrlncRNA signature is a new biomarker for forecasting prognosis and treatment response in cervical cancer.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"580"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959838/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dentate line invasion is a risk factor for locoregional recurrence and distant metastasis following abdominoperineal resection in rectal cancer: a single-centre retrospective cohort study based on 1854 cases.","authors":"Zixing Zhu, Dedi Jiang, Yujuan Jiang, Jichuan Quan, Mingguang Zhang, Wei Pei, Jianjun Bi, Qiang Feng, Haitao Zhou, Zheng Wang, Zhaoxu Zheng, Qian Liu, Zhixun Zhao, Jianwei Liang","doi":"10.1186/s12885-025-14001-6","DOIUrl":"10.1186/s12885-025-14001-6","url":null,"abstract":"<p><strong>Background: </strong>In the context of surgical treatment for rectal cancer, the dentate line is acknowledged as a critical anatomical landmark. However, the prognostic implications of dentate line invasion (DLI) remain elusive and warrant further investigation. This study aims to evaluate and compare the outcomes of patients with rectal cancer who underwent abdominoperineal resection (APR), distinguishing between those with and without DLI.</p><p><strong>Materials and methods: </strong>Between January 2006 and December 2017, this study enrolled 1854 patients with rectal cancer who underwent APR. The cohort was divided into two groups, namely the DLI group (n = 340) and the non-DLI group (n = 1514). The primary endpoints were distant relapse-free survival (DRFS) and local recurrence-free survival (LRFS). Univariate and multivariate analyses were conducted to assess the impact of DLI on DRFS, LRFS, overall survival (OS), and disease-free survival (DFS).</p><p><strong>Results: </strong>The median follow-up duration for the patients was 92.9 months, with a 5-year OS rate of 92.0% for the entire cohort. Compared to the non-DLI group, patients in the DLI group showed significantly poorer outcomes, with 5-year DRFS at 57.4% vs. 73.9% (P < 0.001), DFS at 51.2% vs. 70.7% (P < 0.001), and LRFS at 71.7% vs. 88.5% (P = 0.018). OS was the only metric that showed no significant difference(89.0% vs. 92.6%, P = 0.064). Multivariate analysis demonstrated that DLI negatively impacted DRFS (hazard ratio HR 1.319, P = 0.029), LRFS (HR 2.059, P < 0.001), and DFS (HR 1.563, P < 0.001) as an independent prognostic factor. Furthermore, distant metastasis occurred more frequently in the DLI group (30.0% vs. 23.1%, P = 0.002), along with a higher rate of locoregional recurrence. (16.8% vs. 8.3%, P < 0.001).</p><p><strong>Conclusions: </strong>DLI correlates with a heightened likelihood of locoregional recurrence and distant metastasis among rectal cancer patients treated with APR. This association underscores the significance of DLI as a crucial prognostic factor that should be considered when developing clinical management strategies.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"574"},"PeriodicalIF":3.4,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11956476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FABP4-mediated ERK phosphorylation promotes renal cancer cell migration.","authors":"Evelina La Civita, Rosa Sirica, Felice Crocetto, Matteo Ferro, Francesco Lasorsa, Giuseppe Lucarelli, Ciro Imbimbo, Pietro Formisano, Francesco Beguinot, Daniela Terracciano","doi":"10.1186/s12885-025-13989-1","DOIUrl":"10.1186/s12885-025-13989-1","url":null,"abstract":"<p><p>Clear cell Carcinoma (ccRCC) is the most common and lethal subtype among renal cancers. In the present study we investigated the potential role of fatty acid-binding protein 4 (FABP4), also known as adipocyte FABP (A-FABP) or aP2 on ccRCC progression. Firstly, we found that FABP4 median serum levels were significantly higher in ccRCC patients compared to HD. Based on this result and to evaluate whether FABP4 plays a role on renal cancer malignant phenotype, we analyzed proliferation and migration in 786-O and ACHN cell lines using recombinant FABP4. We found that FABP4 significantly increased cell migration, whereas it had no significant effect on proliferation. As FABP4 is mainly expressed by adipocytes, we measured FABP4 adipocyte conditioned media (Ad-CM) levels showing that Ad-CM from ccRCC (Ad-CM ccRCC) had significantly higher mean values compared to Ad-CM obtained from Healthy Donors (HD). To assess the effects of adipocyte-released FABP-4, on cancer malignant phenotype we evaluated 786-O and ACHN proliferation and migration, using Ad-CM from ccRCC and Ad-CM from HD alone or in combination with FABP4 inhibitor BMS309403. Our results showed that Ad-CM enhanced cell proliferation in ACHN, but not in 786-O and on cell motility in both cell lines and this effect was partially reverted by BMS309403 in both cell lines. Moreover, in both cell lines, FABP4 effect was associated with an increased ERK phosphorylation. Collectively these data support the role of FABP4 in ccRCC progression and its potential use as noninvasive biomarker and therapeutic target for ccRCC.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"575"},"PeriodicalIF":3.4,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11956428/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}